13F Holdings
中文EN

ALEC Alector, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1653087 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY151.1%
TTM net income YoY138.4%
TTM EPS YoY134.0%
Revenue 3-yr CAGR21.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin20.2%
Net margin23.9%
FCF margin-86.5%
EBITDA margin22.6%

Returns

ROE47.5%
ROA16.5%
ROIC (approx.)217.2%
Asset turnover0.69x

Leverage & solvency

Liabilities / assets29.7%
Debt / equity0.00x
Current ratio4.10x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-3.62x
Accruals ratio76.4%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$21.05M$100.56M$97.10M$133.60M$207.09M
R&D expense$123.06M$185.94M$192.12M$210.42M$189.41M
SG&A expense$53.99M$59.62M$56.69M$61.03M$55.04M
Operating income-$156.01M-$145.00M-$151.74M-$137.83M-$37.36M
Pretax income-$142.76M-$118.92M-$125.10M-$130.10M-$36.33M
Income tax$168,000$128,000$5.21M$3.25M$0
Net income-$142.93M-$119.05M-$130.39M-$133.31M-$36.33M
EBITDA-$150.29M-$139.59M-$146.01M-$132.12M-$31.03M
EPS (basic)-1.39-1.23-1.56-1.62-0.45
EPS (diluted)-1.39-1.23-1.56-1.62-0.45
Weighted avg. shares (diluted)103.00M96.59M83.73M82.47M80.42M
Balance sheet
Cash & equivalents$65.80M$34.87M$76.10M$155.79M$330.62M
Short-term investments$190.22M$380.38M$474.31M$558.53M$406.10M
Current assets$266.45M$424.82M$565.81M$726.43M$749.71M
PP&E, net$10.84M$17.14M$21.86M$25.52M$27.33M
Total assets$293.24M$468.30M$621.83M$787.65M$814.66M
Current liabilities$69.50M$125.06M$177.95M$93.81M$139.56M
Short-term debt$366,000$0———
Long-term debt$9.32M$9.39M$0——
Total debt$9.69M$9.39M$0——
Total liabilities$262.59M$341.50M$487.67M$573.21M$513.93M
Shareholders' equity$30.65M$126.80M$134.16M$214.44M$300.72M
Net debt-$56.11M-$25.48M-$76.10M——
Shares outstanding110.36M99.09M84.88M82.90M81.99M
Cash flow statement
Operating cash flow-$184.03M-$229.91M-$184.16M-$20.33M$298.55M
Capital expenditure$41,000$1.25M$2.38M$4.12M$3.25M
Free cash flow-$184.07M-$231.16M-$186.54M-$24.45M$295.30M
Investing cash flow$196.60M$107.13M$101.92M-$159.01M-$49.66M
Financing cash flow$20.21M$81.54M$2.55M$4.51M$30.30M
Depreciation & amortization$5.72M$5.41M$5.72M$5.71M$6.33M
Stock-based compensation$26.66M$39.46M$42.80M$46.15M$40.78M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.